Skip to content

    Recently Viewed

      Listening...

      Home /
      Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting

      Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting

      Share Article
      share to

      New Brunswick, NJ (November 2, 2012) – Janssen and Johnson & Johnson will provide a pre-recorded webcast for investors and other interested parties on Saturday, November 10, at approximately 5:00 p.m., Eastern Time, to coincide with the American College of Rheumatology (ACR) Annual Meeting being held in Washington, D.C.

      The presentation will highlight new, pivotal Phase 3 study findings, including;

      • Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase 3 Trial
      • Ustekinumab in Active Psoriatic Arthritis Including Patients Previously Treated with Anti-TNF Agents: Results of a Phase 3, Multicenter, Double-blind, Placebo-controlled Study; Continued Improvement of Signs and Symptoms in Ustekinumab-treated Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-blind, Placebo-controlled Study

      The pre-recorded webcast with management from the Company’s Janssen pharmaceutical subsidiaries, will provide an update on the Immunology rheumatology pipeline and commercial franchise.

      The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on “Webcasts/Presentations.”

      ###

      Press Contacts:
      Al Wasilewski
      (732) 524-1130

      Bill Price
      (732) 524-6623

      Investor Contacts
      Stan Panasewicz
      (732) 524-2524

      Louise Mehrotra
      (732) 524-6491

      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.